Beth Butler | Charles Explorer

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

2021 | Publikace bez příslušnosti k fakultě